KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Assets (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Return on Assets for 15 consecutive years, with 0.13% as the latest value for Q4 2025.

  • Quarterly Return on Assets fell 8.0% to 0.13% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.13% through Dec 2025, down 8.0% year-over-year, with the annual reading at 0.14% for FY2025, 10.0% down from the prior year.
  • Return on Assets for Q4 2025 was 0.13% at Halozyme Therapeutics, down from 0.28% in the prior quarter.
  • The five-year high for Return on Assets was 0.38% in Q1 2022, with the low at 0.1% in Q1 2023.
  • Average Return on Assets over 5 years is 0.21%, with a median of 0.2% recorded in 2021.
  • The sharpest move saw Return on Assets skyrocketed 36bps in 2021, then fell -28bps in 2023.
  • Over 5 years, Return on Assets stood at 0.35% in 2021, then tumbled by -69bps to 0.11% in 2022, then skyrocketed by 42bps to 0.16% in 2023, then soared by 37bps to 0.21% in 2024, then tumbled by -37bps to 0.13% in 2025.
  • According to Business Quant data, Return on Assets over the past three periods came in at 0.13%, 0.28%, and 0.26% for Q4 2025, Q3 2025, and Q2 2025 respectively.